| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | RenovoCath® (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) locally advanced pancreatic cancer (LAPC) Orphan | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 3 data readout example | RenovoCath® (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) locally advanced pancreatic cancer (LAPC) Orphan | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 3 data readout example | RenovoCath® (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) locally advanced pancreatic cancer (LAPC) Orphan | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
RenovoRx, Inc.
$1.25
-0.07 (-5.3%)
D 24Pipeline Score Pharma · Clinical
Market Cap
56.32 M
EPS
-0.27
P/E Ratio
-
Value Trade
359.41 K
6.84 %
Week
29.52 %
1 Month
36.49 %
3 Month
38.6 %
6 Month
-89.32 %
5 Year
-89.32 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
264.05 K
52 Week Range
0.70 - 1.50
% held by Insiders
3.49 %
% held by Institutions
20.38 %
Enterprise Value
46.84 M
Total Shares
45.09 M
Short %
0.65 %
Float Shares
43.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for RenovoRx, Inc.
224Total events
18Upcoming
35Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T3Enrollment Milestone
Subscribe to view catalyst details
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
▲Patent GrantedRenovoCathFiledIP / Competition
Subscribe to view catalyst details
TBD
▲Enrollment CompleteIAGTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-09 | RenovoCath (novel drug-delivery device) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-12-09 | RenovoCath (novel drug-delivery device) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-12-09 | RenovoCath (novel drug-delivery device) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D24
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 24%
Micro Cap (rank 710 of 933)
Percentile RankRenovoRx, Inc. faces pipeline headwinds (24/100), with 1 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| nab-paclitaxel Small molecule | Locally Advanced Pancreatic Cancer | Phase 3 | NCT03257033 | 42% | - | RECRUITING | 190 | STALLED | C (50) | Sep 1, 2027 | MODERATE_RISK | MEDIUM Aug 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
intra-arterial gemcitabine | locally advanced pancreatic cancer | Phase 3 | 2026-01-09 | systemic levels of gemcitabine: reduced; inactive metabolite levels: increased; correlation: direct correlation was observed between the increased metabolite levels and reduced CA 19-9 Read More | RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 Read More | |
intra-arterial gemcitabine | locally advanced pancreatic cancer | Phase 3 | 2026-01-09 | systemic levels of gemcitabine: reduced; inactive metabolite levels: increased; correlation: direct correlation was observed between the increased metabolite levels and reduced CA 19-9 Read More | RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 Read More | |
intra-arterial gemcitabine | locally advanced pancreatic cancer | Phase 3 | 2026-01-09 | systemic levels of gemcitabine: reduced; inactive metabolite levels: increased; correlation: direct correlation was observed between the increased metabolite levels and reduced CA 19-9 Read More | RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RNXT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RNXT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RNXT▼ -5.3%today
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
RenovoRx has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for ten consecutive business days. CEO Shaun Bagai highlighted recent successes, including record revenue and the completion of enrollment in a significant clinical trial, indicating a positive outlook for future growth.
Read more →RNXTRenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx has received a Notice of Allowance from the USPTO for its patent application related to the RenovoCath device, enhancing its intellectual property portfolio. This patent will provide additional protection for the company's targeted drug-delivery technology, which aims to improve cancer treatment precision. The CEO emphasized the importance of this development for their commercialization strategy and ongoing clinical trials.
Read more →RNXT▲ +12.5%on this news· ran to +25% by day 1
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
RenovoRx reported record revenue of $909,000 for Q2 2026, marking a 61% increase from the previous quarter. The company has expanded the use of its RenovoCath device to treat sarcoma and achieved full enrollment in its Phase III TIGeR-PaC trial. With a positive outlook, RenovoRx raised its annual revenue guidance to between $3.75 million and $4.25 million for 2026.
Read more →RNXTRenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx has successfully completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC). The trial aims to evaluate the efficacy of intra-arterial gemcitabine delivered via the RenovoCath device. Completion of the trial is expected in the first half of 2027, with initial data readout anticipated in the second half of 2027. This milestone reflects strong collaboration and recruitment efforts.
Read more →RNXT▲ +8.5%on this newsshared move
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
RenovoRx has announced the first commercial clinical use of its RenovoCath device for treating a sarcoma patient at CARTI Cancer Center. This marks a significant milestone as the device is also being utilized for pancreatic cancer treatment, showcasing its potential for localized drug delivery in various solid tumors. The company aims to broaden its applications and improve treatment outcomes.
Read more →RNXTRenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
RenovoRx, Inc. will participate in a JonesTrading webinar on August 13, 2026, focusing on its TAMP platform for pancreatic cancer treatment. The event will feature key opinion leaders discussing the evolving treatment landscape and the ongoing Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine. RenovoRx aims to expand its commercial presence and enhance revenue through its FDA-cleared RenovoCath device.
Read more →RNXTRenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
RenovoRx will host its second quarter 2026 financial results conference call on August 12, 2026. The call will cover the company's revenue growth from RenovoCath sales and updates on the Phase III TIGeR-PaC clinical trial for pancreatic cancer. The company has also received FDA Orphan Drug Designation for oxaliplatin.
Read more →RNXTRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
RenovoRx announced a peer-reviewed publication highlighting the successful use of its RenovoCath device for intra-arterial gemcitabine delivery in a patient with locally advanced pancreatic cancer. The case study demonstrated a significant reduction in tumor metabolic activity as observed through PET-CT imaging. The patient underwent eight treatments without complications, showcasing the potential of the TAMP procedure in optimizing cancer therapy.
Read more →RNXT▲ +7.7%on this news
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
RenovoRx announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. The presentation will highlight the company's record Q1 2026 revenue and the accelerating adoption of its RenovoCath drug-delivery device. Additionally, Mr. Bagai will update on the Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine for pancreatic cancer. The company also received FDA Orphan Drug Designation for oxaliplatin, enhancing its oncology pipeline.
Read more →RNXT▲ +6.2%on this news
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
RenovoRx has received FDA Orphan Drug Designation for oxaliplatin, enhancing its pipeline for pancreatic cancer treatment. This marks the company's second designation for pancreatic cancer, highlighting its innovative RenovoCath device's capacity for targeted drug delivery. The designation offers regulatory advantages, including seven years of market exclusivity and financial incentives for clinical research.
Read more →RNXTRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx has announced promising pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial, focusing on the TAMP platform for intra-arterial delivery of gemcitabine. The results indicate that this method may increase local drug potency and decrease systemic exposure, potentially leading to fewer side effects. The findings were published ahead of the ASCO Annual Meeting, highlighting a significant advancement in treatment for locally advanced pancreatic cancer. This research supports the ongoing efforts of RenovoRx to innovate within targeted oncology therapies.
Read more →RNXTRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
RenovoRx, Inc. will present at the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss the company's commercial progress, including record revenue from its RenovoCath device and ongoing clinical trials. The Phase III TIGeR-PaC trial for a novel drug-device combination in pancreatic cancer is nearing full enrollment, with final data expected in mid to late 2027.
Read more →RNXTRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
RenovoRx reported a record revenue of $563,000 for Q1 2026, marking a 136% increase from the previous quarter. The company expanded its active cancer center customers to 16 and anticipates continued growth supported by a robust sales pipeline. The Phase III TIGeR-PaC trial is on track for full enrollment by June 2026, which may further enhance commercial opportunities. RenovoRx ended the quarter with $12.4 million in cash, sufficient to fund operations into at least the second half of 2027.
Read more →RNXTRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to
RenovoRx reported a record revenue of $563,000 for Q1 2026, marking a 136% increase compared to the previous quarter. The company has expanded its active commercial cancer center customers to 16 and continues to build a substantial sales pipeline, with 32 additional centers in various stages of activation. RenovoRx's Phase III TIGeR-PaC trial is on track for full enrollment by June 2026, a critical milestone for the company's dual-track strategy. Additionally, with strong cash reserves, RenovoRx is well-positioned for sustained growth in the coming quarters.
Read more →RNXTThe Most Innovative Medical Device Companies of 2026
The article highlights RenovoRx, Medtronic, Uresta, and Cionic as leading innovators in the medical device industry. It emphasizes a shift from traditional hardware-centric approaches to integrated ecosystems that utilize data, sensors, and adaptive technologies. This transformation aims to enhance the functionality and effectiveness of medical devices.
Read more →RNXTRenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx, Inc. will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026. The company is expected to discuss its positive sales momentum for the RenovoCath device and updates on the Phase III TIGeR-PaC trial for pancreatic cancer. The trial is nearing full enrollment, with completion anticipated in the first half of 2026.
Read more →RNXT▼ -5.1%on this news
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
RenovoRx, Inc. announced that an abstract detailing pharmacokinetic and pharmacodynamic data for its intra-arterial gemcitabine therapy has been accepted for presentation at the 2026 ASCO Annual Meeting. This study investigates the benefits of the IAG therapy in treating locally advanced pancreatic cancer, aiming to enhance drug delivery while minimizing side effects. The presentation is set to occur during the annual meeting from May 29 to June 2, 2026, in Chicago, Illinois. RenovoRx's innovative approach with its drug-delivery device, RenovoCath, is positioned to draw significant attention in the oncology community.
Read more →RNXTClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
RenovoRx presented clinical data at the 2026 SIR Annual Scientific Meeting, highlighting the effectiveness of its TAMP therapy platform for localized chemotherapy delivery in patients with locally advanced pancreatic cancer. The study demonstrated significant reductions in tumor activity through metabolic imaging, suggesting a positive treatment response. TAMP aims to enhance drug delivery while minimizing systemic toxicity.
Read more →RNXTRenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
RenovoRx, Inc. announced that the Japan Patent Office has granted a Notice of Allowance for its first Japanese patent application concerning its RenovoCath device, a patented drug-delivery system targeted at treating tumors. This patent enhances the company's intellectual property portfolio, solidifying its unique approach to localized drug delivery via the vasa vasorum. The device aims to improve patient outcomes by delivering therapies directly to tumor sites, reducing the systemic side effects common with traditional chemotherapy. As RenovoRx commercializes RenovoCath in the U.S., this patent facilitates potential future partnerships and market activities in Japan.
Read more →RNXTRenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
RenovoRx has been named among the World’s Most Innovative Companies for 2026 by Fast Company, ranking 10th in the medical device sector. This recognition highlights the company's innovative work in developing targeted oncology therapies, particularly its RenovoCath drug-delivery device. The FDA-cleared device is designed for the targeted delivery of therapies, potentially improving treatment outcomes for difficult-to-treat tumors. RenovoRx's recent commercial efforts have led to an increase in adoption and revenue generation, indicating positive traction in the oncology market.
Read more →RNXTRenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoRx reported its financial results for 2025, highlighting $1.1 million in revenue from the RenovoCath device. The company is on track to complete enrollment for its Phase III TIGeR-PaC trial by mid-2026, with final data expected in 2027. With $13 million in cash, RenovoRx aims to drive growth and expand its market presence in oncology. The company has seen increasing adoption of RenovoCath across U.S. cancer centers, indicating positive market reception.
Read more →RNXT▼ -5.3%on this newsshared move
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update RenovoCath Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment C
RenovoRx (RNXT) reported its full year 2025 financial results, highlighting its first year of revenue generation of $1.1 million from the RenovoCath device. The company is advancing its Phase III TIGeR-PaC trial with patient randomization on track for full enrollment by mid-2026. With $13 million in cash, RenovoRx plans to enhance its commercial growth and supports ongoing developments in targeted oncology therapies. The expansion includes a growing network of cancer centers utilizing the RenovoCath platform, indicating promising future revenue potential.
Read more →RNXT▲ +5.5%on this newsshared move
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
RenovoRx has achieved a significant milestone in its Phase III TIGeR-PaC trial, surpassing 100 randomized patients. The company is on track to complete enrollment by mid-2026, with final data expected in 2027. The trial evaluates the efficacy of intra-arterial gemcitabine delivered via the RenovoCath device for treating locally advanced pancreatic cancer.
Read more →RNXT▲ +11%on this newsshared move
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
RenovoRx has successfully closed an oversubscribed private placement, raising approximately $10 million. The financing was supported by institutional investors and insiders, showcasing confidence in the company's growth strategy. The funds will be used to accelerate the commercialization of RenovoCath and support the pivotal Phase III TIGeR-PaC clinical trial. The company anticipates significant milestones and revenue growth in the coming years.
Read more →RNXTRenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
RenovoRx will host a conference call on March 30, 2026, to discuss its Q4 and full-year 2025 financial results. The call will highlight the adoption of RenovoCath in cancer centers and provide updates on the Phase III TIGeR-PaC clinical trial for pancreatic cancer. The company aims to broaden its clinical pipeline and commercial activities.
Read more →RNXTRenovoRx Announces $10 Million at Market Private Placement
RenovoRx, Inc. has announced a successful $10 million private placement to bolster its cash position and support its commercialization efforts for RenovoCath. The financing was oversubscribed and led by prominent life science institutional investors, with participation from the company's management. The funds will help advance the pivotal Phase III TIGeR-PaC trial in pancreatic cancer and aim for cash-flow breakeven operations by mid-2026.
Read more →RNXT▲ +6.6%on this newsshared move
RenovoRx Announces $10 Million at Market Private Placement Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data Oversubscribed
RenovoRx, Inc. has announced a $10 million private placement aimed at enhancing its cash position to support important milestones such as achieving breakeven operations and advancing its pivotal Phase III clinical trial for locally advanced pancreatic cancer. The financing, led by notable life science institutional investors and supplemented by investments from company executives and board members, is expected to close on March 20, 2026. RenovoRx plans to utilize the proceeds to boost commercialization efforts for its FDA-cleared RenovoCath device and enhance revenue generation.
Read more →RNXTRenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx has significantly increased the adoption of its FDA-cleared device, RenovoCath, with 12 U.S. cancer centers now utilizing it and 33 centers requesting access. The company has successfully completed over 700 procedures since its FDA clearance in 2014. The appointment of Dr. Ramtin Agah as Executive Chairman is expected to further enhance clinical adoption and commercial growth as the company aims for revenue expansion in 2026.
Read more →RNXTRenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx announced the acceptance of a clinical data abstract at the 2026 Society of Interventional Radiology Annual Scientific Meeting. The abstract, submitted by experts from Moffitt Cancer Center, investigates the efficacy of the company's TAMP therapy for pancreatic cancer. The presentation is scheduled for April 13, 2026, in Toronto, highlighting the potential benefits of targeted chemotherapy delivery.
Read more →RNXTMark Voll Joins RenovoRx as Chief Financial Officer
RenovoRx Inc. has appointed Mark Voll as its new Chief Financial Officer, effective February 1. Voll brings over 30 years of financial leadership experience, having successfully guided several high-growth public companies through commercial development. His previous roles include CFO positions at multiple publicly traded technology firms.
Read more →RNXTWhy Commercial Discipline Starts Long Before Launch
RenovoRx, led by CEO Shaun Bagai, focuses on innovative oncology therapies, particularly through its FDA-cleared device, RenovoCath. This device utilizes the Trans-Arterial Micro-Perfusion (TAMP) platform for targeted drug delivery, aiming to address significant medical needs while minimizing toxicity. The article emphasizes the importance of commercial discipline prior to product launch.
Read more →RNXTRenovoRx Establishes RenovoCath® Medical Advisory Board
RenovoRx has established a Medical Advisory Board (MAB) to enhance its clinical and strategic initiatives for the RenovoCath device. The MAB consists of leading interventional radiology experts who will provide insights to support ongoing clinical trials and market strategies. This development aims to improve targeted drug delivery for difficult-to-treat cancers.
Read more →RNXTRenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
RenovoRx has appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. With over 30 years of experience, Voll will play a crucial role in stockholder communications and financial strategy as the company commercializes its RenovoCath device and advances its Phase III clinical trial. This appointment comes as RenovoRx transitions into a commercial entity.
Read more →RNXTRenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
RenovoRx announced that new clinical data supporting its TAMP therapy platform will be presented at the SIO Annual Scientific Meeting on February 6, 2026. The study, led by Dr. Christopher Laing, focuses on real-time intra-arterial pressure measurements during TAMP procedures, highlighting its potential to optimize chemotherapy delivery in challenging tumors. The findings suggest that pressure monitoring can enhance treatment effectiveness.
Read more →RNXT▲ +6.6%on this news
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx announced the acceptance of its clinical data abstract for the 2026 Society of Interventional Oncology Annual Scientific Meeting. The study focuses on optimizing drug delivery in solid tumors using the TAMP therapy platform and RenovoCath device. Researchers will present findings that may enhance individualized treatment approaches.
Read more →RNXTInterview with Shaun Bagai: Revolutionary Cancer Treatment, Startup Success, & Medtech Mentorship
Shaun Bagai, CEO of RenovoRx, discusses his journey from a Silicon Valley startup to leading a MedTech firm. He emphasizes the importance of mentorship, hiring for cultural fit, and balancing empowerment with accountability. Bagai reflects on the significance of values-driven leadership and the role of genuine networking in building a successful MedTech career.
Read more →RNXTRenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
RenovoRx has successfully expanded the adoption of its RenovoCath device to nine cancer centers, including City of Hope and Moffitt. This growth reflects the company's effective commercialization efforts and the increasing demand for targeted oncology therapies. The RenovoCath device aims to enhance chemotherapy delivery while minimizing systemic side effects, particularly for patients with challenging tumors like locally advanced pancreatic cancer.
Read more →RNXTRenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
RenovoRx, Inc. will participate in the AlphaNorth Capital Event from January 16-18, 2026, where CEO Shaun Bagai will discuss the company's commercial progress and ongoing Phase III clinical trial for intra-arterial gemcitabine. The event highlights the increasing adoption of RenovoCath, a targeted drug-delivery device, among cancer centers. RenovoRx aims to expand its clinical utility and revenue-generating activities.
Read more →RNXTNanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer
The article discusses breakthroughs in cancer drug delivery, highlighting the FDA's approval of nanoparticle-based therapies and antibody-drug conjugates. It anticipates future innovations in the field, featuring insights from leading companies on novel delivery systems and technologies. The advancements aim to improve targeted treatment for cancer patients.
Read more →RNXTRenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
RenovoRx announced promising new clinical data from its ongoing Phase III TIGeR-PaC trial, which will be presented at ASCO GI 2026. The data suggests that the TAMP therapy platform may enhance the efficacy of intra-arterial gemcitabine while reducing systemic side effects compared to standard intravenous chemotherapy. This approach could offer a significant advancement in treating locally advanced pancreatic cancer.
Read more →RNXTRenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
RenovoRx announced the acceptance of its clinical data abstract for the ASCO Gastrointestinal Cancers Symposium 2026. The abstract will present findings from a pharmacokinetic and pharmacodynamic sub-study of the ongoing Phase III TIGeR-PaC trial, comparing intra-arterial gemcitabine delivery to standard intravenous chemotherapy for locally advanced pancreatic cancer. The presentation is scheduled for January 9, 2026.
Read more →RNXT▼ -6.6%on this news
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025. The presentation will cover updates on the company's commercial efforts, including the financial performance and ongoing clinical trials, particularly the Phase III TIGeR-PaC trial for pancreatic cancer. The company is experiencing increased demand for its RenovoCath device, underscoring its market traction.
Read more →RNXTRevolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai
In a recent MedTech 101 episode, RenovoRx CEO Shaun Bagai discusses advancements in cancer treatment, particularly for pancreatic cancer. He highlights the company's localized therapy platform, which delivers chemotherapy directly to tumors, minimizing systemic side effects. The conversation emphasizes the importance of patient-centric innovation and the agility of startups in the medtech space. Bagai expresses optimism about the future of oncology and drug delivery systems.
Read more →RNXT▼ -6.4%on this news
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
RenovoRx CEO Shaun Bagai is set to present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20, 2025. The presentation will cover the company's commercial efforts, including the growing adoption of its FDA-cleared RenovoCath device. Additionally, Bagai will discuss advancements in clinical research, particularly the Phase III TIGeR-PaC trial for pancreatic cancer.
Read more →RNXT▼ -23%on this newsshared move
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
RenovoRx reported its third quarter 2025 financial results, highlighting approximately $900,000 in year-to-date revenue and significant growth in the adoption of its RenovoCath device. The company has expanded its customer base from 5 to 14 cancer centers and is progressing in its Phase III TIGeR-PaC trial. Despite a net loss of $2.9 million, management remains optimistic about future revenue growth and market demand.
Read more →RNXT▲ +7.4%on this news· ran to -25% by day 3shared move
First Patient Treated in RenovoCath Clinical Trial
RenovoRx Inc. has successfully treated its first patient in a clinical trial for its FDA-cleared drug delivery device, RenovoCath, at the University of Vermont Cancer Center. The trial has expanded to include Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center as additional sites. The study is led by notable principal investigators from these institutions.
Read more →RNXT▼ -6.2%on this newsshared move
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
RenovoRx has appointed Dr. Timothy Donahue, a leading pancreatic cancer expert, to its Scientific Advisory Board. Dr. Donahue, who is affiliated with UCLA, brings extensive experience in pancreatic surgery and translational oncology. His involvement is expected to enhance the development of RenovoRx's localized therapies aimed at improving outcomes for patients with challenging tumors.
Read more →RNXT▼ -6.4%on this newsshared move
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
RenovoRx CEO Shaun Bagai will participate in the Canaccord Genuity Forum on November 20, 2025, to discuss the company's commercialization progress and ongoing Phase III clinical trials for its drug-device combination product. The forum will highlight the market demand for RenovoCath, a targeted drug-delivery device, and the company's efforts to evaluate long-term safety and survival outcomes for patients. The event will take place in New York City.
Read more →RNXTRenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
RenovoRx, Inc. will host a conference call on November 13, 2025, to discuss its third quarter financial results and business highlights. The call will cover advancements in the commercialization of its RenovoCath device and updates on the Phase III TIGeR-PaC trial for pancreatic cancer. Interested parties can access a recording of the call afterward.
Read more →RNXT▼ -7.4%on this news
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
RenovoRx has appointed Dr. Thierry de Baère, an esteemed interventional oncologist, to its Scientific Advisory Board. His expertise in minimally invasive cancer therapies is expected to bolster RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform. This strategic addition aims to enhance the company's efforts in improving treatment outcomes for patients with difficult-to-treat tumors.
Read more →RNXTExpanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots
RenovoRx is advancing targeted oncology treatments with its FDA-cleared RenovoCath device, which utilizes the TAMP therapy platform for precise drug delivery to tumors. CEO Shaun Bagai discusses recent patents and ongoing clinical trials, highlighting the company's innovative approach to cancer care. The discussion also mentions an upcoming presentation at SSO 2025.
Read more →RNXTFrom Trials to Hope: A New Approach to Treating Pancreatic Cancer
RenovoRx is pioneering a new method to deliver chemotherapy directly to pancreatic tumors, aiming to enhance treatment efficacy while minimizing side effects. CEO Shaun Bagai highlighted the potential of this approach to significantly improve the quality of life for patients with locally advanced pancreatic cancer. Ongoing clinical trials are showing promising progress, offering hope to patients and their families.
Read more →RNXTRenovoRx Panther Study Progresses with First Clinical Procedure
RenovoRx has launched its PanTheR post-marketing registry, completing the first procedure at the University of Vermont Cancer Center. This registry will gather real-world data on safety and outcomes for patients treated with RenovoCath. The company is also advancing its Phase III TIGeR-PaC trial while establishing a device-centric evidence base to support broader adoption of its technology.
Read more →RNXTRenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
RenovoRx has successfully completed the first patient procedure in its PanTheR Post-Marketing Registry Study at the University of Vermont Cancer Center. The study aims to evaluate the safety and effectiveness of the RenovoCath device in treating solid tumors. Two additional clinical sites, Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center, have joined the study, which is expected to gather valuable real-world data on patient outcomes.
Read more →RNXTHow Skipping The CRO Helped RenovoRx Get Closer To Patients
RenovoRx has opted to conduct its Phase 3 TIGer-PaC trial without a CRO, leveraging in-house expertise. Chief Clinical Officer Leesa Gentry discusses how this decision enhances patient engagement and streamlines trial execution. The trial focuses on delivering chemotherapy directly to patients with locally advanced pancreatic cancer.
Read more →RNXT▲ +6%on this news
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference on September 16-17, 2025. He will discuss the company's commercialization efforts and the ongoing Phase III TIGeR-PaC clinical trial for its drug-device combination product aimed at treating locally advanced pancreatic cancer. The trial has received a recommendation to continue based on interim analysis results.
Read more →RNXTPharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma
The PharmaShots webinar highlighted the importance of patient-centric approaches in biopharma. Industry leaders and patient advocates discussed strategies to enhance treatment outcomes and bridge the gap between patients and biopharma companies. The session emphasized that prioritizing patients is essential for driving innovation in the industry.
Read more →RNXTRenovoRx Updates Pivotal TIGeR-PaC Trial of Pancreatic Cancer Treatment
RenovoRx, Inc. has provided an update on its pivotal phase 3 TIGeR-PaC trial, which is assessing its investigational drug-device combination for treating locally advanced pancreatic cancer. The trial employs the TAMP transarterial microperfusion therapy platform using RenovoCath for administering gemcitabine. The study requires 114 randomized patients and 86 events for final analysis.
Read more →RNXTRenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
RenovoRx, Inc. announced a strong financial performance for the second quarter of 2025, with over $400,000 in revenue attributed to its RenovoCath device. The Independent Data Monitoring Committee has recommended the continuation of the pivotal Phase III TIGeR-PaC trial based on promising interim reviews. The company has also seen an increase in customer interest and orders from cancer treatment centers, indicating robust market demand. Amidst this growth, RenovoRx plans to further bolster its sales team to enhance market penetration in the coming years.
Read more →RNXTRenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
RenovoRx has expanded its commercialization efforts for the RenovoCath device, now approved by 13 cancer centers. The company has seen repeat orders from four active customers, indicating strong demand for its innovative drug-delivery technology. To further enhance its strategy, RenovoRx has appointed Philip Stocton as Senior Director of Sales and Market Development. The ongoing Phase III TIGeR-PaC trial may also lead to additional customers post-enrollment.
Read more →RNXTRenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
RenovoRx has announced the launch of the PanTheR Post-Marketing Registry Study to evaluate the safety and effectiveness of its FDA-cleared RenovoCath device in treating solid tumors. Patient enrollment is set to begin at several esteemed cancer centers, including the University of Vermont Cancer Center. This study aims to gather real-world data to enhance treatment strategies and patient outcomes.
Read more →RNXTRenovoRx Launches Post-Marketing Study to Advance Real-World Use of RenovoCath Device
RenovoRx has initiated the PanTheR study to assess the long-term safety and effectiveness of the RenovoCath device in treating solid tumors. The University of Vermont Cancer Center is the first site to enroll patients, with additional sites anticipated by September 2025. This study aims to collect real-world data to enhance understanding of the device's performance.
Read more →RNXT▲ +5.7%on this news· ran to +16% by day 3
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights Q1 2025 RenovoCath Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase O
RenovoRx reported its financial results for the first quarter of 2025, with revenues of around $200,000 from its RenovoCath device, surpassing expectations. The company has secured approximately $14.6 million in purchase orders, which is anticipated to support the ongoing commercialization efforts and the Phase III TIGeR-PaC clinical trial. Enrollment for the trial is on track, with additional cancer centers joining the initiative. Despite positive revenue trends, the company also noted an increase in net loss and operational expenses during this quarter.
Read more →RNXTU.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
RenovoRx has received a new patent from the U.S. Patent Office for its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which enhances methods for localized drug delivery near tumors. This patent, effective May 6, 2025, extends protection until November 2037. The company now holds 19 issued patents, bolstering its commercialization efforts for the RenovoCath device and supporting its ongoing Phase III clinical trial for treating locally advanced pancreatic cancer.
Read more →RNXTJohns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
RenovoRx has initiated patient enrollment at Johns Hopkins Medicine for its Phase III TIGeR-PaC clinical trial, targeting locally advanced pancreatic cancer. This addition to the trial's network of clinical sites aims to enhance patient enrollment by 2025. Dr. Valerie Lee has been appointed as Principal Investigator, further strengthening the trial's leadership.
Read more →RNXTRenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial Revenues from RenovoCath Expected to Grow Sequentially During 2025 with Expan
RenovoRx, Inc. reported its initial revenues from the commercialization of RenovoCath, generating approximately $43,000 in Q4 2024. The company expects substantial revenue growth from increased customer orders anticipated throughout 2025, with targeted market opportunities indicating a potential $400 million in U.S. sales. Additionally, RenovoRx provided updates on its Phase III TIGeR-PaC clinical trial, highlighting ongoing patient enrollment and a forthcoming interim analysis. The firm maintains a solid cash position to support its operational strategy and expansion efforts.
Read more →RNXTRenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
RenovoRx presented new human pharmacokinetic data at the SSO 2025 Annual Meeting, highlighting the efficacy of its Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The data indicates that localized delivery of gemcitabine using the RenovoCath device results in lower systemic drug levels compared to traditional intravenous methods. This approach may minimize chemotherapy-related toxicities, particularly for patients with locally advanced pancreatic cancer.
Read more →RNXTRenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
RenovoRx's TAMP therapy platform has been recognized for its innovative approach to targeted drug delivery, showing significant improvements in local tissue concentration of chemotherapy. The peer-reviewed paper will be honored at the SIR 2025 Annual Scientific Meeting, where findings will be presented. This recognition underscores the potential benefits of TAMP in treating solid tumors.
Read more →RNXTRenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
RenovoRx announced a presentation of new pre-clinical data at the Society of Surgical Oncology 2025 Annual Meeting. The abstract supports their Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which aims to improve treatment efficacy and safety for patients with locally advanced pancreatic cancer. The ongoing Phase III TIGeR-PaC trial is evaluating the investigational drug-device combination product candidate, IAG.
Read more →RNXTRenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
RenovoRx has announced new purchase orders for its RenovoCath device from high-volume National Cancer Institute-designated centers. The company expects to generate initial revenues this quarter, with a potential market of $400 million annually. The positive reception and repeat orders from initial customers suggest strong demand and validation for the device's therapeutic delivery capabilities.
Read more →RNXT▼ -11.2%on this news
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
RenovoRx presented promising pre-clinical data at the SIO 2025 Annual Conference, showcasing its TAMP therapy platform's potential to enhance localized drug delivery in challenging cancers. The study demonstrated improved drug penetration in tumors with limited blood supply using the RenovoCath device. The findings suggest that TAMP could revolutionize cancer treatment approaches, particularly for pancreatic adenocarcinoma.
Read more →RNXTRenovoRx Announces Proposed Public Offering
RenovoRx, a life sciences company, has announced the commencement of an underwritten public offering of its common stock and pre-funded warrants. The proceeds from this offering are intended to fund working capital and advance their ongoing Phase III TIGeR-PaC study as well as commercial activities for their delivery platform, RenovoCath. The offering is subject to market conditions, with no assurances on completion or terms. The company has noted initial commercial interest with received purchase orders for RenovoCath, a device aimed at enhancing targeted cancer therapy.
Read more →RNXTRenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
RenovoRx presented promising pharmacokinetic data from its TIGeR-PaC Phase III clinical trial at ASCO GI 2025. The data suggests that intra-arterial delivery of gemcitabine via the TAMP therapy platform may enhance local drug potency and reduce systemic side effects. This approach could represent a significant advancement in treating locally advanced pancreatic cancer.
Read more →RNXTRenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
RenovoRx announced the acceptance of three abstracts for presentation at prestigious oncology conferences in 2025. These abstracts support the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, showcasing additional human pharmacokinetic data and pre-clinical results. The ongoing Phase III TIGeR-PaC clinical trial is evaluating the efficacy of gemcitabine delivered via TAMP for treating locally advanced pancreatic cancer.
Read more →RNXT▲ +9.4%on this news
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
RenovoRx has announced its strong intellectual property position, holding 18 issued patents and 13 pending as it advances its commercialization and clinical trial plans for 2025. The company is focusing on its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to enhance targeted drug delivery for cancer treatments. Additionally, RenovoRx is progressing with its pivotal Phase III TIGeR-PaC clinical trial, evaluating its first product candidate, a novel oncology drug-device combination.
Read more →RNXTRenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
RenovoRx, Inc. has announced the initiation of patient enrollment for its pivotal Phase III TIGeR-PaC clinical trial at SCRI Oncology Partners for the treatment of locally advanced pancreatic cancer. The trial will utilize the innovative TAMP™ therapy platform to deliver gemcitabine in a targeted manner. Dr. Meredith Pelster will serve as the principal investigator, emphasizing the potential for improved survival rates and minimized side effects compared to standard chemotherapy. Enrollment is expected to continue through the first half of 2025, adding to the extensive network of SCRI's clinical trial sites across the U.S.
Read more →RNXTRenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
RenovoRx, Inc. (RNXT) is set to host an investor fireside chat on December 17, 2024, led by CEO Shaun Bagai. The discussion will focus on the company's 2024 achievements, including its commercialization strategy for the RenovoCath delivery system and the ongoing TIGeR-PaC Phase III clinical trial for treating locally advanced pancreatic cancer. Notably, the meeting will provide insights into upcoming milestones such as interim data readouts expected in 2025. This event is open for all interested parties to participate.
Read more →RNXTRenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
RenovoRx has received its first purchase orders for the FDA-cleared RenovoCath delivery system, marking a significant step in its commercialization strategy. Over ten medical institutions have begun the procurement process, indicating strong demand. The company estimates a potential market size of several hundred million dollars for RenovoCath, which utilizes the patented TAMP therapy platform. RenovoRx is also focused on its Phase III TIGeR-PaC clinical trial for a drug-device combination targeting locally advanced pancreatic cancer.
Read more →RNXT▲ +16%on this newsshared move
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System
RenovoRx, Inc. has announced the receipt of its first purchase orders for the RenovoCath device, a significant milestone in its commercialization strategy. More than ten medical institutions across the U.S. have initiated the purchase process, validating the unmet needs in the oncology market. The company estimates the potential market size for RenovoCath could reach several hundred million dollars annually. Additionally, RenovoRx continues to focus on its Phase III TIGeR-PaC clinical trial for a combination treatment targeting locally advanced pancreatic cancer, which is set for further progress in 2025.
Read more →RNXTInterventional Approaches for Locally Advanced Pancreatic Cancer
Dr. Ripal Gandhi discusses innovative interventional approaches for treating locally advanced pancreatic cancer, highlighting the intra-arterial use of the Renovo catheter in a phase 3 trial. He emphasizes the goal of extending patient survival while maintaining quality of life. The presentation also covers novel transvenous techniques and their potential benefits.
Read more →RNXTNorthwell Health Cancer Institute launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx has announced that Northwell Health Cancer Institute is enrolling patients in its pivotal Phase III TIGeR-PaC clinical trial, which evaluates the TAMP therapy platform for treating locally advanced pancreatic cancer. The study aims to demonstrate improved efficacy and reduced side effects compared to standard chemotherapy. RenovoRx is targeting full patient enrollment by the first half of 2025.
Read more →RNXTRenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath Delivery System in Both Direct and Commercial Partner Ch
RenovoRx reported its third quarter 2024 financial results, noting significant advancement in its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, with patient enrollment expected to complete in the first half of 2025. The company has $9.6 million in cash, allowing continued support for clinical activities and a commercialization strategy for its FDA-cleared RenovoCath delivery system, projecting potential revenue generation in 2025. Although there were positive developments, the company recorded an increased net loss compared to the same period last year.
Read more →RNXTRenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
RenovoRx is ramping up production of its FDA-cleared RenovoCath delivery system in response to heightened demand from oncology and interventional radiology specialists. The company has strengthened its partnership with Medical Murray to facilitate this increase and is exploring standalone commercial opportunities for RenovoCath. Concurrently, RenovoRx continues its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, with additional clinical sites joining to expedite patient enrollment.
Read more →RNXTRenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians Company expands relationship with manufacturing partner Medical M
RenovoRx, Inc. announced it will increase production of its FDA-cleared RenovoCath delivery system, responding to strong demand from oncology and interventional radiology physicians. The company has expanded its partnership with Medical Murray for manufacturing and is exploring commercial opportunities for RenovoCath beyond existing clinical programs. RenovoRx is also engaged in a pivotal Phase III clinical trial for the treatment of locally advanced pancreatic cancer, with plans for a commercial strategy expected to generate revenue in 2025. The company is actively discussing potential sales and distribution partnerships for RenovoCath as a standalone device.
Read more →RNXTRenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx, Inc. announced that Dr. Ripal Gandhi will present at the upcoming Symposium on Clinical Interventional Oncology, highlighting the TAMP therapy platform aimed at treating locally advanced pancreatic cancer (LAPC). The presentation will address the efficacy and challenges of current standard care treatments, emphasizing the potential of TAMP as a targeted option. Additionally, Dr. Gandhi will discuss findings from ongoing Phase III clinical trials and related publications, indicating promising research into the delivery of chemotherapy through this innovative platform.
Read more →RNXTRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York
RenovoRx, Inc. announced that CEO Shaun Bagai will present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024. The presentation will cover corporate achievements, including updates on the pivotal Phase III TIGeR-PaC clinical trial for its TAMP™ therapy platform aimed at treating Locally Advanced Pancreatic Cancer. Additionally, Bagai will outline ongoing efforts in business development and the strategic appointment of Ryan Witt as Senior VP of Corporate Strategy and Partnerships, enhancing commercialization efforts.
Read more →RNXTRenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx has announced the enrollment of its first patient in the Phase III TIGeR-PaC clinical trial at the University of Nebraska Medical Center (UNMC) for Locally Advanced Pancreatic Cancer (LAPC). This trial is utilizing RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform to assess the efficacy of the drug-device combination, RenovoGem. The trial aims to improve upon the standard systemic chemotherapy by targeting the cancerous tumor directly via intra-arterial delivery. UNMC's participation adds to a growing list of esteemed sites collaborating in this pivotal trial.
Read more →RNXTRenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®
RenovoRx announced the publication of positive early-stage clinical data on its TAMP therapy for Locally Advanced Pancreatic Cancer (LAPC) in The Oncologist. The study indicates that TAMP significantly improves overall survival compared to traditional chemotherapy. The ongoing Phase III trial aims to further validate these findings and assess TAMP's safety and efficacy.
Read more →RNXT▼ -7%on this newsshared move
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist
RenovoRx announced the publication of early-stage clinical data in The Oncologist, highlighting the efficacy of its TAMP therapy for Locally Advanced Pancreatic Cancer (LAPC). The study demonstrated a median overall survival of 27 months, suggesting significant advantages over traditional systemic chemotherapy. Despite showing promise, the therapy carries risks of gastrointestinal side effects and rare serious complications such as sepsis. TAMP is currently being compared in a Phase III trial against the standard of care to validate its benefits in this challenging patient population.
Read more →RNXTRenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
RenovoRx announced the acceptance of its manuscript for publication in The Oncologist, detailing clinical data on its TAMP therapy for Locally Advanced Pancreatic Cancer (LAPC). The publication is expected in Summer 2024 and includes findings from foundational studies on the safety and efficacy of the therapy. The ongoing Phase III TIGeR-PaC trial continues to evaluate this innovative treatment approach.
Read more →RNXT▲ +6.6%on this newsshared move
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist
RenovoRx, Inc. announced the acceptance of a manuscript for publication in The Oncologist, detailing clinical data from their studies on treating Locally Advanced Pancreatic Cancer (LAPC) using their TAMP therapy platform. The publication highlights survival rates from their Phase I/II studies and draws on data from a separate observational registry. RenovoRx is conducting an ongoing Phase III trial, TIGeR-PaC, which compares TAMP therapy to standard chemotherapy. The results aim to assess the safety and efficacy of this novel treatment approach in LAPC patients.
Read more →RNXTUniversity of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx has announced that the University of Nebraska Medical Center is enrolling patients for its pivotal Phase III TIGeR-PaC clinical trial, which investigates the effectiveness of RenovoGem in treating Locally Advanced Pancreatic Cancer. The trial aims to compare the novel TAMP therapy with the current standard of care, systemic intravenous chemotherapy. This study is significant as pancreatic cancer has a low survival rate, and the innovative approach may enhance treatment efficacy.
Read more →RNXT▼ -5.1%on this news· ran to -20% by day 1
Trans-Arterial Micro-Perfusion For Improved Drug Delivery
The article discusses trans-arterial micro-perfusion (TAMP), a novel technique for drug delivery directly to tumor sites. This method addresses the challenges posed by hypovascular tumors, which limit the effectiveness of systemic therapies. TAMP aims to enhance precision medicine by targeting specific tumor regions, thereby reducing systemic toxicity and improving therapeutic concentration.
Read more →RNXTRenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
RenovoRx, a clinical-stage biopharmaceutical company focused on precision oncology, has appointed Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships. Witt brings 15 years of experience in medical technology and biopharmaceutical strategy, having previously served in key roles in multiple organizations. His expertise is expected to enhance RenovoRx’s efforts to advance its Phase III clinical trial and explore new commercial opportunities. This appointment aligns with the company's goal of improving therapeutic outcomes for cancer patients using its drug-delivery technology.
Read more →RNXTPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Deliver
RenovoRx announced the publication of pre-clinical studies supporting its TAMP therapy platform, which significantly enhances drug delivery to solid tumors. The studies indicate a 100-fold increase in local tissue concentration compared to traditional methods, potentially improving treatment efficacy and safety. The ongoing Phase III TIGeR-PaC trial aims to validate these findings for locally advanced pancreatic cancer.
Read more →RNXTRenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement
RenovoRx, Inc. has regained compliance with Nasdaq's stockholders' equity requirement, following a successful fundraising effort. This development means their scheduled hearing regarding compliance will no longer take place, allowing the company to avoid further scrutiny. With $17.2 million in gross proceeds secured, RenovoRx aims to focus on advancing their pivotal Phase III TIGeR-PaC clinical trial for pancreatic cancer and expanding their Trans-Arterial Micro-Perfusion development pipeline. The company remains committed to delivering innovative cancer therapies to improve patient outcomes.
Read more →RNXT▲ +5.3%on this newsshared move
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx presented a clinical data abstract at the 2024 SIR Annual Scientific Meeting, highlighting a sub-study from the Phase III TIGeR-PaC trial. The study examined Mesenteric Venous Thrombosis (MVT) as a predictor of treatment outcomes in patients with locally advanced pancreatic cancer. Results indicated that MVT significantly impacted the ability to complete TAMP therapy, suggesting a need for better patient risk stratification.
Read more →RNXT▼ -5.7%on this newsshared move
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx has sufficient funding to advance pivotal Phase III clini
RenovoRx, Inc. has completed a private placement raising approximately $11.1 million, adding to a total of $17.2 million raised in 2024. This funding will support their pivotal Phase III clinical trial for locally advanced pancreatic cancer and allow for the expansion of their oncology development pipeline. The CEO highlighted the importance of these milestones for the company's future, emphasizing the potential to improve cancer treatments with their novel delivery technologies.
Read more →RNXTRenovoRx Announces $11.1 Million At Market Private Placement Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial thr
RenovoRx, Inc. announced an $11.1 million private placement to fund its operations through 2026. The financing will support the company's pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer and enable the expansion of its TAMP clinical development pipeline. The trial aims to assess the efficacy of RenovoRx's proprietary TAMP therapy compared to standard chemotherapy, with significant events anticipated in late 2024. The expected closing date for the private placement is April 11, 2024, subject to standard closing conditions.
Read more →RNXTRenovoRx Highlights Key Leadership Promotions
RenovoRx has announced the promotion of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. Gentry will oversee clinical and regulatory operations, while Kocak will manage financial reporting and strategic planning. These promotions aim to strengthen the company's leadership as it advances its clinical programs, particularly the Phase III TIGeR-PaC study for RenovoGem in treating locally advanced pancreatic cancer.
Read more →RNXT▲ +15.2%on this news· ran to +40% by day 3
RenovoRx Closes $6.1 Million Private Placement With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late
RenovoRx, Inc. has successfully closed a $6.1 million private placement to bolster its financial position as it advances its pivotal TIGeR-PaC Phase III clinical trial for locally advanced pancreatic cancer. The participation of insiders, including management and board members, reflects confidence in the company's strategy. The funds will extend the company's cash runway through late 2024 and allow for further engagement in clinical trials. Despite the positive developments, the company acknowledges the ongoing need for additional funding to explore new indications.
Read more →RNXTRenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
RenovoRx has announced the initiation of the CouGar Trial, its second Phase III clinical study, focusing on the treatment of unresectable locally advanced extrahepatic cholangiocarcinoma (bile duct cancer). Oklahoma University Health has been designated as the first clinical site for this trial, which aims to evaluate the efficacy of RenovoGem, a combination drug-device therapy. The trial seeks to address the urgent need for effective treatments in a cancer type known for its poor prognosis and limited options.
Read more →RNXT▼ -8.2%on this news· ran to +29% by day 3shared move
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx announced the acceptance of a clinical data abstract for its lead product candidate, RenovoGem, at the 2024 Society of Interventional Radiology Annual Scientific Meeting. The abstract will focus on the company's proprietary TAMP therapy platform for treating Locally Advanced Pancreatic Cancer. CEO Shaun Bagai expressed enthusiasm about presenting their research at this significant conference.
Read more →RNXT▲ +20.8%on this newsshared move
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
RenovoRx has filed an international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, aiming to enhance its IP coverage. This new patent could facilitate the delivery of a wider range of therapeutic agents, including those for DNA/RNA alterations and cell therapies. The company is also progressing in its Phase III clinical trial for treating locally advanced pancreatic cancer with gemcitabine.
Read more →RNXTRenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
RenovoRx has appointed Dr. Michel Ducreux to its Scientific Advisory Board, bringing extensive expertise in gastrointestinal oncology. Dr. Ducreux is excited to contribute to RenovoRx's innovative clinical programs, particularly its trans-arterial micro-perfusion platform, which aims to improve treatment outcomes for difficult-to-access tumors. This appointment is expected to enhance the company's research and development initiatives.
Read more →RNXT▼ -28.3%on this news· ran to -43% by day 3
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights Collaboration with Imugene further validates TAMP TM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRx's delivery platform b
RenovoRx, a clinical-stage biopharmaceutical company, reported its third quarter 2023 financial results, highlighting positive developments for its TAMP therapy platform in the Phase III clinical trial for pancreatic cancer. The interim analysis completed in March 2023 recommended the continuation of the study, with the potential for significant survival benefits. Collaboration with Imugene further validates this therapy platform, extending its application beyond chemotherapy to immunotherapy. However, the company reported a net loss for the quarter, alongside increased research and development expenses as they advance clinical trials.
Read more →RNXTIntra-Arterial Approach to Locally Advanced Pancreatic Cancer
The article discusses the effectiveness of catheter-based localized drug delivery for cancer treatment, highlighting its reduced systemic toxicity. It notes the challenges posed by hypovascular tumors, such as pancreatic cancer, which lack clear arterial feeder vessels. Novel drug delivery methods are suggested to potentially enhance patient outcomes and survival rates.
Read more →RNXT▲ +7.6%on this news
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights Presented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overal
RenovoRx reported strong financial results and operational highlights for Q2 2023, showcasing positive interim data from its Phase III TIGeR-PaC study. The data revealed an 8-month delay in cancer progression for patients treated with RenovoGem, along with a 6-month overall survival benefit and a 65% reduction in adverse effects. The company has also launched a collaboration with Imugene to explore innovative treatment delivery for metastatic pancreatic cancer. Furthermore, RenovoRx made strategic appointments to its leadership and advisory teams to bolster its clinical operations.
Read more →RNXTIntra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
At the 2023 World Congress on Gastrointestinal Cancers, Dr. Michael Pishvaian presented promising interim data from a phase 3 study on intra-arterial gemcitabine for patients with locally advanced pancreatic cancer. The findings suggest potential benefits of this treatment approach, highlighting its relevance in oncology.
Read more →RNXTRenovoRx Presents Positive Interim Phase III Data in Pancreatic Cancer
RenovoRx announced positive interim results from the Phase 3 TIGeR-PaC study, focusing on the use of RenovoGem for treating locally advanced pancreatic cancer. The findings, which indicate improved progression-free survival, were presented at the 2023 ESMO World Congress. Dr. Michael Pishvaian from Johns Hopkins Medicine led the presentation.
Read more →RNXTRenovoRx, Imugene Partner to Deliver Oncolytic Virus Therapy
RenovoRx and Imugene have formed a strategic research collaboration to enhance the delivery of Imugene's oncolytic virus therapy using RenovoRx's TAMP platform. This partnership aims to improve treatment options for challenging tumors like pancreatic and liver cancers by utilizing trans-arterial delivery methods. The collaboration could provide significant benefits over traditional therapy administration.
Read more →RNXTRenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration
RenovoRx and Imugene have formed a strategic research collaboration to enhance the delivery of Imugene's CF33 oncolytic virus therapy using RenovoRx's TAMP platform. This partnership aims to optimize treatment for challenging tumors, leveraging both companies' innovative technologies. The collaboration highlights the potential for improved cancer therapies through targeted delivery methods.
Read more →RNXTRenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
RenovoRx and Imugene have announced a collaboration to optimize the delivery of Imugene's CF33 oncolytic virus using RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) platform. This partnership aims to enhance treatment for challenging tumors, such as those in the pancreas and liver, by allowing localized delivery. The TAMP platform has shown promising results in increasing drug concentration in target tissues compared to traditional methods.
Read more →RNXTSurvival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer
The phase 3 TIGeR-PaC study revealed that intra-arterial administration of gemcitabine (RenovoGem) significantly improves progression-free survival and overall survival in patients with locally advanced pancreatic cancer. In a study of 23 patients, RenovoGem showed a median progression-free survival of 15 months and an overall survival of 16 months, outperforming the standard treatment.
Read more →RNXT▲ +10.9%on this news
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights Announced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGem TM C
RenovoRx, Inc. announced its first-quarter 2023 financial results, highlighting a positive interim analysis from its Phase III TIGeR-PaC clinical trial. The analysis showed a 60% survival benefit and over 65% reduction in side effects for patients using RenovoGem compared to systemic chemotherapy. The company also appointed key industry veterans to its leadership team and successfully closed a $5 million registered direct offering. Financially, RenovoRx reported a net loss of $3.3 million for the quarter, and it has plans to proceed with further trials to explore the potential of RenovoGem in other cancer types.
Read more →RNXT▲ +11.9%on this news
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors Los Altos, CA
RenovoRx, Inc. has appointed Dr. Robert J. Spiegel to its Board of Directors, effective April 25, 2023. Dr. Spiegel brings over 40 years of biopharmaceutical experience, including significant roles at Schering-Plough and PTC Therapeutics. The company aims to advance discussions with the FDA regarding their therapy, RenovoGem, which is currently in a Phase III trial for locally advanced pancreatic cancer. RenovoRx's drug-delivery platform, RenovoTAMP, is designed to improve the efficacy and safety of oncological treatments.
Read more →RNXT▼ -13.6%on this news
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RenovoRx, Inc. has announced a definitive securities purchase agreement for a registered direct offering of approximately $5 million. The company will sell 1,557,632 shares of its common stock at $3.21 each. The proceeds from this offering will be used for working capital and general corporate purposes. Additionally, warrants to purchase further shares will be issued concurrently. The closing of the offering is expected around April 3, 2023, pending customary conditions.
Read more →RNXTRenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone First of Two Planned Interim Analyses Triggered Company and Data Monitoring Committee Conducting Review Re
RenovoRx, Inc. has reported its financial results for 2022, highlighting the achievement of a significant clinical trial milestone in the ongoing Phase III TIGeR-PaC study for treating locally advanced pancreatic cancer. The company has randomized 47 patients and triggered the first interim analysis, which is expected to be reported soon. Despite a net loss of $9.9 million, management remains optimistic about the potential of its proprietary therapy platform and plans for future trials.
Read more →RNXT▼ -7.6%on this news· ran to -33% by day 3
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem TM Supports Potential for RenovoTAMP Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects
RenovoRx announced promising initial results from a pharmacokinetic substudy of its RenovoTAMP therapy platform at the ASCO GI Cancers Symposium. The findings suggest that intra-arterial administration of gemcitabine via RenovoTAMP leads to higher local drug concentration and significantly reduced systemic exposure. This could greatly diminish the side effects commonly associated with traditional intravenous chemotherapy. Further research and presentations are planned to explore these findings' impact on patient quality of life and extending survival rates.
Read more →RNXTRenovoRx Reports Third Quarter 2022 Financial Results Los Altos, CA
Reports Third Quarter 2022 Financial Results Altos, CA, November 14, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTA
Read more →RNXTRenovoRx Appoints Angela Gill Nelms as Chief Operating Officer Los Altos, CA
Appoints Angela Gill Nelms as Altos, CA, September 19, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP ) therapy p
Read more →RNXTRenovoRx Reports Second Quarter 2022 Financial Results Los Altos, CA
Reports Second Quarter 2022 Financial Results Altos, CA, August 15, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAM
Read more →RNXTRenovoRx Appoints James Ahlers as Chief Financial Officer Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller Los Altos, CA
Appoints James Ahlers as Chief Financial Officer Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller Altos, CA, July 19, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announc
Read more →RNXTRenovoRx Reports First Quarter 2022 Financial Results Los Altos, CA
Reports First Quarter 2022 Financial Results Altos, CA, May 16, 2022 - RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 202
Read more →RNXTRenovoRx Reports Full Year 2021 Financial Results Los Altos, CA
Reports Full Year 2021 Financial Results Altos, CA, March 30, 2022 - RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021.
Read more →RNXTRenovoRx Announces Third Quarter 2021 Financial Results Los Altos, CA
Announces Third Quarter 2021 Financial Results Altos, CA, November 15, 2021 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September third quarter
Read more →RNXTRenovoRx and Parexel Biotech Reach Key Milestone in Clinical Trial for Locally-Advanced Pancreatic Cancer
LOS ALTOS, Calif. and BOSTON and DURHAM, N.C., Jan. 13, 2020 (GLOBE NEWSWIRE) -- RenovoRx, Inc., an innovator in targeted cancer therapy, and Parexel Biotech, a division of Parexel, one of the world’s leading global clinical research organizations (CROs) focused on accelerating t
Read more →Competitive Position
How RNXT ranks across every disease it competes inCompetitive Position is a premium feature
See how RNXT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial